期刊文献+

美国FDA药品上市后风险管理措施研究及对我国的启示——以沙利度胺为例 被引量:3

Research on post-marketing drug risk management measures of FDA and its implication for China: a case of thalidomide
原文传递
导出
摘要 通过研究美国FDA对沙利度胺上市后风险管理的实例,为我国药品风险管理制度的有效实施提供参考。主要采用文献研究法和案例分析法,通过查阅FDA药品上市后风险管理指南及法规,分析典型案例沙利度胺重新上市后实施的风险管理措施。针对已知毒性药物沙利度胺,美国FDA和药品生产厂商共同制定风险管理计划,采取一系列干预措施,包括登记注册项目、提供可获得性证明、知识测试等,直接作用于处方医师、药师、患者等多个环节,同时定期评估风险控制效果以不断完善,有效地控制沙利度胺严重风险,发挥其临床价值。美国药品上市后风险管理的理念和手段值得我国借鉴。 The aim of the article is to study the post-marketing risk management of thalidomide in the United States in order to provide the implication for the development of risk management system in China.The literature research and case analysis were mainly used to analyze the post-marketing risk management measures of thalidomide,and FDA’s post-marketing relevant guidelines and regulations were reviewed.For the known toxic drug thalidomide,FDA and drug manufacturers jointly formulated a risk management plan and adopted a series of interventions,including registration projects,provision of proof of availability,KAP testing and other tools,directly acting on physicians,pharmacists,patients,and relevant participants.And the evaluation of its effectiveness was regularly implemented,so as to effectively control the serious risks of thalidomide.The concept and methods of post-marketing risk management of FDA are worthy of being referred by our country.
作者 陈锦敏 柳鹏程 余正 CHEN Jin-min;LIU Peng-cheng;YU Zheng(School of International Pharmaceutical Business,Nanjing 211198,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2020年第23期2654-2659,共6页 Chinese Journal of New Drugs
关键词 美国FDA 上市后风险管理 风险管理措施 沙利度胺 FDA post-market risk management risk management measures thalidomide
  • 相关文献

参考文献5

二级参考文献26

  • 1戴钟英.妊娠期用药FDA五级分类法[J].继续医学教育,2005,19(5):11-13. 被引量:7
  • 2郭晓昕,武志昂,张承绪.美国食品药品监督管理局对上市药品的特殊风险管理措施[J].中国医药导刊,2006,8(4):301-303. 被引量:4
  • 3FDA.Guidance for industry premarketing risk assessment[EB/OL].http://www.fda.gov/cder/guidance/6357fnl.pdf,2005-03-01.
  • 4ICH E1A.The extent of population exposure to assess clinical safetyfor drugs intended for long-term treatment of non-life-threatening conditions[EB/OL].http://www,fda.gov/cder/guidance/ichela,pdf,1995-O3-01.
  • 5FDA.Guidance for industry good pharmacovigilance practices and pharmacoepide miologic assessment[EB/OL] http://www.fda.gov/cder/guidance/6359OCC,pdf,2005-03-01.
  • 6FDA.Guidance for industry development and use of risk minimization action plans[EB/OL].http://www,fda.gov/cder/guidance/6358fnl.pdf,2005-03-01.
  • 7Guidance for industry development and use of risk minimization action plan[ EB/OL]. (2005 -07 - 20) [2010 - 10 - 30 ]. http:// www. fda. gov/ohrms/dockets/ac/OS/briefinge/2005 - 4136bl_ 03_ Risk% 20Minimization% 20Action% 20Plans. pdf.
  • 8国家食品药品监督管理局.国家食品药品监督管理局提醒警惕异维A酸的严重皮肤损害及其他使用风险[EB/OL].(2010-08-11)[2010-10-30].http://www.sda.gov.cn/WS01/CL0051/52338.html.
  • 9FDA. Information for healthcare professionals: isotretinoin (marketed asaccutane) [EB/OL]. (2005 -07 -20) [2010-10- 30 ]. http://www, fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085227, htm.
  • 10FDA. FDA and manufacturers of accutane and its generics to implement IPLEDGE program on March 1, 2006 [ EB/OL ]. (2006 - 02 - 23 ) [ 2010 - 10 - 30 ]. http://www, fda. gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108605. htm.

共引文献22

同被引文献75

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部